Vol 4, No 1 (2019)
Case report
Published online: 2018-12-19
Biphosphonates-related osteonecrosis of the jaw
Medical Research Journal 2019;4(1):58-62.
Abstract
The relationship between osteonecrosis of the jaw and bisphosphonate therapy has been described
recently. Although bisphosphonates have a long list of benefits in the treatment of patients with bone
metastases, an increasing number of reports describe the complication of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Bisphosphonates are synthetic analogues of pyrophosphate that inhibit
bone resorption. The aetiology of BRONJ is unclear. It starts as aseptic necrosis, with a surgical procedure
involving an interruption in the continuity of the oral mucosa as an obligatory precondition. Subsequently,
areas of osteonecrosis occur and detach from the surrounding areas of purulent inflammation or can be
removed surgically. Due to the limited treatment options, conservative treatment supported by antibiotic
and surgical therapy is used. This article describes a case of BRONJ.
Keywords: bisphosphonateosteonecrosisjawsosteoporosis
References
- Litwiniuk M, Staszkiewicz A. Martwica kości szczęk po długotrwałym stosowaniu bisfosfonianów. Onkol Prakt Klin. 2007; 3: 306–310.
- Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005; 104(1): 83–93.
- Marcinkowska-Suchowierska W, Talalaj M. Czerwińska E, Wąsowski M. Leczenie osteoporozy farmakologiczne – zasadność jej stosowania i wyboru leku. Postępy Nauk Med. 2006; 4: 172–178.
- Borgioli A, Viviani C, Duvina M, et al. Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations. Ther Clin Risk Manag. 2009; 5(1): 217–227.
- American Association of Oral and Maxillofacial Surgeons. Position Paper on Bisphospho-nate-Ralated Osteonecrosis of the Jaws. 2007; 65: 369–376.
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9): 1115–1117.
- Frank S, Fiołna K, Wojtowicz A. Bisphosphonate-related osteonecrosis of the jaw. A review of the literature. DENTAL FORUM 2013; 2, XLI. : 79–82.
- Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3): 415–423.
- Chmielewska E, Kafarski P. Synthetic Procedures Leading towards Aminobisphosphonates. Molecules. 2016; 21(11): 1474.
- American Association of Oral and Maxillofacial Surgeons. Position paper on bisphospho-nate-related osteonecrosis of the jaws, approved by the Board of Trustees September 25, 2006. http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf ( 2008 Dec 6).
- Guo LR, Bao SS, Li YZ, et al. Ag(I)-mediated formation of pyrophosphonate coupled with C-C bond cleavage of acetonitrile. Chem Commun (Camb). 2009(20): 2893–2895.
- Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002; 8(5): 1080–1084.
- Choi JY, Kim HJ, Lee YC, et al. Inhibition of bone healing by pamidronate in calvarial bony defects. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103(3): 321–328.
- Aspenberg P. Osteonecrosis of the jaw: what do bisphosphonates do? Expert Opin Drug Saf. 2006; 5(6): 743–745.
- Dodson TB, Raje NS, Caruso PA, et al. Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med. 2008; 358(12): 1283–1291.
- Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010; 48(3): 221–223.
- Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144(10): 753–761.
- de Oliveira CC, Brizeno LA, de Sousa FB, et al. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review. Med Oral Patol Oral Cir Bucal. 2016; 21(4): e431–e439.
- Sarasquete ME, González M, San Miguel JF, et al. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis. 2009; 15(6): 382–387.
- Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11): 1567–1575.
- Boonyapakorn T, Schirmer I, Reichart PA, et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008; 44(9): 857–869.
- Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007; 18(10): 1363–1370.
- Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005; 353(1): 99–102; discussion 99.
- Karna H, Gonzalez J, Radia HS, et al. Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses. Oral Oncol. 2018; 85: 15–23.
- Amantea M, Cristofaro MG, Giudice A, et al. Oseonecrosis drug-induced (bisphospho-nates) of the jaws. J Cranio-Maxilloofac Surg. 2008; 36(suppl 1): S36.
- Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol. 2007; 78(3): 584–594.
- Edwards B, Hellstein J, Jacobsen P, et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy. The Journal of the American Dental Association. 2008; 139(12): 1674–1677.
- Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102(4): 433–441.
- Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006; 2(1): 7–14.